Request a Call

Request a Call from a
representative

MED INFO LIVE CHAT

Chat with a medical
information specialist

Information for:

UK & IRELAND HEALTHCARE PROFESSIONALS

Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)


Information intended for:

PATIENTS PRESCRIBED PRADAXA®/ MEMBERS OF THE PUBLIC IN THE UK & IRELAND

Click here for more information on Pradaxa®


PC-GB -101423 V1 August 2020

Calculate your potential cost savings
with Pradaxa (dabigatran etexilate)®
versus other NOACs

Cost

How much could you save by prescribing Pradaxa® (dabigatran etexilate) for your patients with non-valvular atrial fibrillation versus other NOACs? Use the simple cost calculator below to find out. 

Calculator

 

If you switch your eligible patients to Pradaxa®, your potential yearly savings are

 

£0.00

Prices based on NHS list price.1
Annual savings per patient are calculated by multiplying the difference in the daily price of each drug relative to Pradaxa® by 365. The total savings are calculated by multiplying the savings per patient on apixaban, rivaroxaban and edoxaban by the number of patients receiving them, respectively. This calculator assumes that all of your NOAC patients are suitable for Pradaxa®. Please refer to the Pradaxa® Summary of Product Characteristics to ensure your patient is appropriate for Pradaxa® prior to prescribing.2,3

Abbreviations

NOAC — non-vitamin K antagonist oral anticoagulant

References
  1. MIMS.co.uk (accessed July 2020).
  2. Pradaxa® 150mg hard capsules Summary of Product Characteristics.
  3. Pradaxa® 110mg hard capsules Summary of Product Characteristics.
PC-GB-101176 V1 | August 2020

Disclaimer

You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.